Conclusions There is no evidence to support differences in the effects of long-acting GH compared with those of daily GH .
Purpose Long-acting growth hormone ( GH ) has been developed to address the noncompliance and decreased efficacy associated with daily GH injections .
We aim ed to evaluate the efficacy and safety of long-acting GH replacement therapy in children with short stature .
Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency.
CONTEXT LB03002 is a novel sustained-release GH preparation administered once weekly . OBJECTIVE Our objective was to examine the pharmacokinetics , pharmacodynamics , and safety of LB03002 vs. daily GH . DESIGN AND SETTING This open-label , crossover study compared the pharmacokinetics and pharmacodynamics of LB03002 and daily GH . PATIENTS AND OTHER PARTICIPANTS Six male and three female patients with adult GH deficiency participated in the single-center study . INTERVENTION Subjects were on stable daily GH treatment  before the study . After a 4-wk washout with no GH , five weekly doses of LB03002 were given . MAIN OUTCOME MEASURE GH and IGF-I concentrations were measured during the last dose of daily GH and during the first and fifth weekly doses of LB03002 . RESULTS The observed maximal serum GH concentration was approximately doubled after LB03002 ( 6.1 + /- 3.2 and 4.5 + /- 2.2 microg/liter at first and fifth doses ) compared with daily GH ( 2.7 + /- 2.2 microg/liter ) . A sustained increase in GH concentration for more than 48 h was observed with LB03002 , such that dose-normalized area under the curve ( AUC ) was not significantly different between daily GH and LB03002 . Mean maximal serum IGF-I concentration was 34 - 41 % greater with LB03002 than with daily GH , and AUC was 7-fold greater . However , normalized to GH dose , AUC for IGF-I was comparable . Adverse events and local reactions were acceptable , and there were no evident safety concerns with LB03002 . CONCLUSIONS Multiple weekly doses of LB03002 appeared safe and well tolerated . Comparable GH bioavailability and sustained IGF-I elevations support the use of once-weekly LB03002 to replace daily GH therapy
Conclusions There is no evidence to support differences in the effects of long-acting GH compared with those of daily GH .
Purpose Long-acting growth hormone ( GH ) has been developed to address the noncompliance and decreased efficacy associated with daily GH injections .
We aim ed to evaluate the efficacy and safety of long-acting GH replacement therapy in children with short stature .